# Phospholipase D: emerging therapeutic targets in signaling, metabolism, and immune-oncology

## TL;DR

This paper reviews how the PLD enzyme family regulates signaling, metabolism, and immunity, and highlights its potential as a target for treating cancer, autoimmune diseases, and metabolic disorders.

## Contribution

The paper provides a comprehensive overview of PLD isoform-specific roles in disease mechanisms and emphasizes the need for isoform-specific inhibitors for therapeutic development.

## Key findings

- PLD isoforms regulate key signaling pathways like Wnt/β-catenin, PKC, and mTOR.
- PLD activity influences immune responses, glucose metabolism, and tumor microenvironment remodeling.
- Dysregulated PLD is linked to metabolic syndrome, autoimmune diseases, and cancer progression.

## Abstract

The phospholipase D (PLD) family, comprising six evolutionarily conserved isoforms (PLD1-6), serves as master regulators of lipid signaling, membrane dynamics, and cellular communication. Functional divergence driven by structural heterogeneity enables PLD-mediated control of signal transduction, metabolic homeostasis, and immune responses. Activated by stimuli like growth factors and hormones, PLD governs core signaling networks, including Wnt/β-catenin, protein kinase C (PKC), and mammalian target of rapamycin (mTOR) pathways while modulating glucose uptake and lipid metabolism. PLD isoforms coordinate adaptive and innate immunity through T/B cell activation, macrophage polarization, and cytokine regulation. Dysregulated PLD activity promotes metabolic syndrome, autoimmune diseases, and remodeling of the tumor immune microenvironment, positioning PLD as a therapeutic target. This review integrates isoform-specific mechanisms in signaling, metabolism, immunity and tumor microenvironment, and underscores the critical need for isoform-specific inhibitors to dissect pathological mechanisms and advance disease understanding. By deconvoluting PLD’s pleiotropic roles across signaling axis, lipid-glucose crosstalk, and immune circuitry, this work delineates a roadmap for developing targeted combinatorial therapies that exploit PLD’s spatial-temporal regulation of cellular homeostasis.

The phospholipase D (PLD) enzyme family serves as a central regulatory node governing interconnected biological processes, including cellular signal transduction, metabolic reprogramming, and immunomodulatory networks, particularly within tumor-immune microenvironment dynamics. A comprehensive understanding of PLD's molecular underpinnings in these cascades holds significant translational potential for developing targeted therapies against cancer, autoimmune disorders, and metabolic diseases.